ArticleGut pathogens2009
Probiotics and gastrointestinal disease: successes, problems and future prospects.
Article in Gut pathogens, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02155972 (The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression), which is not on this map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial
Who cites it
65 citing papers in PubMed.
- Molecules produced by probiotics prevent enteric colibacillosis in pigs.BMC veterinary research · 2017Trial
- Evaluation of probiotic potential of bacteria isolated from black tiger (Penaeus monodon) for aquaculture application.Journal, genetic engineering & biotechnology · 2026Article
- Weissella as a core member of the Gir cow milk microbiome: functional insights.Antonie van Leeuwenhoek · 2026Article
- Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens.Gut microbes · 2025Review
- Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases.Advanced drug delivery reviews · 2025Review
- Comprehensive in vitro and whole-genome characterization of probiotic properties in Pediococcus acidilactici P10 isolated from Iranian broiler chicken.Scientific reports · 2025Article
- Commercial utilization of bacteriocins: tackling challenges and exploring their potential as alternatives to antibiotics.Future microbiology · 2025Review
- Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies.Probiotics and antimicrobial proteins · 2025Review
- Impact of Freezing and Freeze Drying onFoods (Basel, Switzerland) · 2025Article
- Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Engineered Probiotic-Based Biomaterials for Inflammatory Bowel Disease Treatment.Theranostics · 2025Review
- Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.European journal of medical research · 2024Review
- Review
- In Vitro Effects of Postmetabolites fromMicroorganisms · 2024Article
- Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.Journal of personalized medicine · 2024Review
- Biotics and bacterial function: impact on gut and host health.The ISME journal · 2024Review
- Probiotics Show Promise as a Novel Natural Treatment for Neurological Disorders.Current pharmaceutical biotechnology · 2024Review
- An exploratoryMicrobiome research reports · 2024Review
- Article
- Antioxidant and Antibacterial Effects of Potential Probiotics Isolated from Korean Fermented Foods.International journal of molecular sciences · 2022Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal disease is a major cause of morbidity and mortality worldwide each year. Treatment of chronic inflammatory gastrointestinal conditions such as ulcerative colitis and Crohn's disease is difficult due to the ambiguity surrounding their precise aetiology. Infectious gastrointestinal diseases, such as various types of diarrheal disease are also becoming increasingly difficult to treat due to the increasing dissemination of antibiotic resistance among microorganisms and the emergence of the so-called 'superbugs'. Taking into consideration these problems, the need for novel therapeutics is essential. Although described for over a century probiotics have only been extensively researched in recent years. Their use in the treatment and prevention of disease, particularly gastrointestinal disease, has yielded many successful results, some of which we outline in this review. Although promising, many probiotics are hindered by inherent physiological and technological weaknesses and often the most clinically promising strains are unusable. Consequently we discuss various strategies whereby probiotics may be engineered to create designer probiotics. Such innovative approaches include; a receptor mimicry strategy to create probiotics that target specific pathogens and toxins, a patho-biotechnology approach using pathogen-derived genes to create more robust probiotic stains with increased host and processing-associated stress tolerance profiles and meta-biotechnology, whereby, functional metagenomics may be used to identify novel genes from diverse and vastly unexplored environments, such as the human gut, for use in biotechnology and medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.